Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuangdan Mingmu Capsule
- Development stage
- Unknown
- Lead developer
- Beijing Qihuang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shuangdan Mingmu Capsule (SDMM) is a Traditional Chinese Medicine (TCM) herbal formulation developed and manufactured by Beijing Qihuang Pharmaceutical for the treatment of diabetic retinopathy. Administered orally as a capsule, it is composed of 11 medicinal ingredients, including *Ligustrum lucidum*, *Eclipta*, *Panax notoginseng*, and *Salvia*. The drug is approved in China (SFDA Z20080062) and has been evaluated in Phase IV clinical trials. Its therapeutic mechanism involves the regulation of microRNA expression (specifically miR-450b-5p, miR-1249, and miR-155-5p) and the reduction of oxidative stress-induced apoptosis in retinal pericytes through the PARP/GAPDH signaling pathway. Clinical research indicates it improves retinal morphology, restores ganglion cell layer cell numbers, and alleviates systemic diabetic symptoms such as polyuria and polydipsia.
- Brand names
- Shuangdan Mingmu CapsuleShuangdan Mingmu Jiaonang双丹明目胶囊
- Other names
- SDMM
02
Targets
miR-155-5p (MicroRNA 155-5p)GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)PARP (PARP family)miR-450b-5p (MicroRNA 450b-5p)
Beyond the preview
Go deeper on Shuangdan Mingmu Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shuangdan Mingmu Capsule.